TARS

Tarsus Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website arsusrx.com
Employees(FY) 87
ISIN US87650L1035

Performance

+3.58%

+12.84%

+52.92%

+93.95%

+161.28%

YTD

+164.42%

Profile

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Advanced Technical Analysis

Technical Analysis of TARS 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 70 further supports this positive outlook. However, the Oscillators Score of 43 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TARS

Stock Rank

Recent News & Updates

2024-12-04 09:55
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet(Zacks)
2024-11-18 09:55
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade(Zacks)
2024-11-15 08:38
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-11-14 08:35
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating(MT Newswires)
2024-11-14 02:15
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...(GuruFocus.com)
2024-11-13 17:30
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-11-13 16:35
Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges(MT Newswires)
2024-11-13 16:05
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements(GlobeNewswire)
2024-11-13 08:30
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors(GlobeNewswire)
2024-11-13 03:05
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements(Globenewswire)
2024-11-12 19:30
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors(Globenewswire)
2024-11-07 10:00
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?(Zacks)
2024-11-06 16:30
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024(GlobeNewswire)
2024-11-06 03:30
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024(Globenewswire)
2024-11-05 08:30
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer(GlobeNewswire)
2024-11-04 19:30
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer(Globenewswire)
2024-10-30 06:39
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?(Zacks)
2024-10-18 06:41
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?(Zacks)
2024-10-17 08:30
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%(GlobeNewswire)
2024-10-16 20:30
Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25%(Globenewswire)
2024-10-09 17:56
Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...(GuruFocus.com)
2024-09-25 17:00
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024(GlobeNewswire)
2024-09-25 05:00
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024(Globenewswire)
2024-08-28 17:00
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference(GlobeNewswire)
2024-08-28 05:00
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference(Globenewswire)
2024-08-11 08:20
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues(Simply Wall St.)
2024-08-09 09:00
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating(MT Newswires)
2024-08-08 18:05
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates(Zacks)
2024-08-08 16:05
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements(GlobeNewswire)
2024-08-08 09:56
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024(Investorplace)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.